Concepedia

Laurence E. Burgess

LE

Statistics

Publications

27

Citations

1.9K

H-Index

21

Active since

1991

Affiliations

Array BioPharma (United States)(Current)

Amgen (United States)

Mirati Therapeutics (United States)

EKOS Corporation

Pfizer (United States)

Laurence E. Burgess is an author at Array BioPharma (United States) specializing in medicinal chemistry, drug discovery, and pharmacology.

Publications per year

1991–2024

27

Publications

27

Identification of the Clinical Development Candidate <b>MRTX849</b>, a Covalent KRAS<sup>G12C</sup> Inhibitor for the Treatment of Cancer

Jay B. Fell, John P. Fischer, Brian R. Baer et al. · Journal of Medicinal Chemistry · 2020 · 594 citations · Full text

, , +17

A simple asymmetric synthesis of 2-substituted pyrrolidines and 5-substituted pyrrolidinones

Laurence E. Burgess, A. I. MEYERS · The Journal of Organic Chemistry · 1992 · 154 citations

, , +8

Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity

Jay B. Fell, John P. Fischer, Brian R. Baer et al. · ACS Medicinal Chemistry Letters · 2018 · 108 citations · Full text

, , +15

Chemoproteomic discovery of a covalent allosteric inhibitor of WRN helicase

Kristen A. Baltgalvis, Kelsey N. Lamb, Kent T. Symons et al. · Nature · 2024 · 102 citations

, , +16

Tetrazole and ester substituted tetrahydoquinoxalines as potent cholesteryl ester transfer protein inhibitors

C. Todd Eary, Zachary S. Jones, Robert D. Groneberg et al. · Bioorganic & Medicinal Chemistry Letters · 2007 · 87 citations · Full text

, , +7

1–5 of 27